/Companies

SymKardia

Westlake, US · Founded 2024 · Delaware corporation

Find your way into SymKardia

148 people in our graph can introduce you to the SymKardia team.

Sign up to see every warm intro you have to SymKardia

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the SymKardia team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

SymKardia develops a selective cardiac neuromodulation therapy to treat cardiac arrhythmias such as atrial fibrillation, targeting the nervous system rather than only cardiac tissue. It is a clinical-stage cardiovascular medical device company running pre-clinical and clinical research programs.

Founders & leadership

SGSteven Girouard
Steven GirouardExecutive
JPJonathan Piccini
Jonathan PicciniExecutive
DSDwight Skinner
Dwight SkinnerChief Operating OfficerDwight Skinner has over 25 years of experience in medical device product development, with expertise in implantable electrical stimulation systems, cardiac leads, and neuromodulation therapies. He holds a Design for Six Sigma Master Black Belt certification and brings knowledge of regulatory and manufacturing standards including ISO 10993 biocompatibility and MRI safety.
ILImad Libbus
Imad LibbusChief Scientific Officer
BKBruce KenKnight
Bruce KenKnightChief Executive Officer
AC
Anthony CaparsoExecutive

Board

RP
Robert PicarelBoard director
CR
Claudio RumazzaBoard director
AS
Arun SridharBoard director
AG
Alain Garcinuno ColletBoard director
JB
James BlouzardBoard director

Reported raises · per SEC filings

Form D private placements

$500K disclosed across 1 round · 2026

▶$500KraisedJun 2026 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert PicarelDirector
  • Steven GirouardExecutive Officer
  • Claudio RumazzaDirector
  • Jonathan PicciniExecutive Officer
  • Dwight SkinnerExecutive Officer
  • Imad LibbusExecutive Officer
  • Arun SridharDirector
  • Bruce KenKnightExecutive Officer
  • Anthony CaparsoExecutive Officer, Director
  • Alain Garcinuno ColletDirector
  • James BlouzardDirector
Offering amount
$4M
Amount sold
$500K
First sale
Jun 2026
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Companies working in the same space as SymKardia.

Frequently asked questions

What does SymKardia do?
SymKardia develops a selective cardiac neuromodulation therapy to treat cardiac arrhythmias such as atrial fibrillation, targeting the nervous system rather than only cardiac tissue. It is a clinical-stage cardiovascular medical device company running pre-clinical and clinical research programs.
How much funding has SymKardia raised?
SymKardia has disclosed $500K raised across 1 round.
Where is SymKardia headquartered?
SymKardia is headquartered in Westlake, US.